{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T18:57:23Z","timestamp":1793041043344,"version":"4.5.0"},"reference-count":46,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T00:00:00Z","timestamp":1757980800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["23ck0106890h0002"],"award-info":[{"award-number":["23ck0106890h0002"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.esmoop.2025.105851","type":"journal-article","created":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T13:04:50Z","timestamp":1761829490000},"page":"105851","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["FGFR2-IIIc isoform detection reveals prognostic prevalence and a functional link to mesenchymal transition in gastric and gastroesophageal junction cancer"],"prefix":"10.1016","volume":"10","author":[{"given":"T.","family":"Hashimoto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Iida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Kadowaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Makiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Machida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Boku","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Kudo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Oki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Ohtsubo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Kawakami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Okano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Komatsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Yuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Sakamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Kuwata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Yamashita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Amisaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Shibuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Imai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Fujisawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Bando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Shitara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Yoshino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10258","key":"10.1016\/j.esmoop.2025.105851_bib1","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1016\/S0140-6736(20)30925-9","article-title":"Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019","volume":"396","year":"2020","journal-title":"Lancet"},{"issue":"10294","key":"10.1016\/j.esmoop.2025.105851_bib2","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","article-title":"First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial","volume":"398","author":"Janjigian","year":"2021","journal-title":"Lancet"},{"issue":"10389","key":"10.1016\/j.esmoop.2025.105851_bib3","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1016\/S0140-6736(23)00620-7","article-title":"Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial","volume":"401","author":"Shitara","year":"2023","journal-title":"Lancet"},{"issue":"10418","key":"10.1016\/j.esmoop.2025.105851_bib4","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1016\/S0140-6736(23)02033-0","article-title":"Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial","volume":"402","author":"Janjigian","year":"2023","journal-title":"Lancet"},{"issue":"7890","key":"10.1016\/j.esmoop.2025.105851_bib5","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1038\/s41586-021-04161-3","article-title":"The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer","volume":"600","author":"Janjigian","year":"2021","journal-title":"Nature"},{"issue":"11","key":"10.1016\/j.esmoop.2025.105851_bib6","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1016\/S1470-2045(22)00603-9","article-title":"Bemarituzumab in patients with FGFR2b-selected gastric or gastro-oesophageal junction adenocarcinoma (FIGHT): a randomised, double-blind, placebo-controlled, phase 2 study","volume":"23","author":"Wainberg","year":"2022","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.esmoop.2025.105851_bib7","doi-asserted-by":"crossref","first-page":"626","DOI":"10.2741\/4609","article-title":"Role of fibroblast growth factor receptor-2 splicing in normal and cancer cells","volume":"23","author":"Ishiwata","year":"2018","journal-title":"Front Biosci (Landmark Ed)"},{"issue":"9","key":"10.1016\/j.esmoop.2025.105851_bib8","doi-asserted-by":"crossref","first-page":"2460","DOI":"10.1158\/1078-0432.CCR-12-3708","article-title":"Tumor-specific isoform switch of the fibroblast growth factor receptor 2 underlies the mesenchymal and malignant phenotypes of clear cell renal cell carcinomas","volume":"19","author":"Zhao","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.esmoop.2025.105851_bib9","doi-asserted-by":"crossref","DOI":"10.1155\/2021\/9955456","article-title":"2b or not 2b: how opposing FGF receptor splice variants are blocking progress in precision oncology","volume":"2021","author":"Epstein","year":"2021","journal-title":"J Oncol"},{"issue":"17","key":"10.1016\/j.esmoop.2025.105851_bib10","doi-asserted-by":"crossref","first-page":"4569","DOI":"10.1158\/1078-0432.CCR-19-4088","article-title":"FGFR2c mesenchymal isoform expression is associated with poor prognosis and further refines risk stratification within endometrial cancer molecular subtypes","volume":"26","author":"Sengal","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105851_bib11","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/s12964-020-00582-1","article-title":"Role of PKC\u03b5 in the epithelial-mesenchymal transition induced by FGFR2 isoform switch","volume":"18","author":"Ranieri","year":"2020","journal-title":"Cell Commun Signal"},{"issue":"4","key":"10.1016\/j.esmoop.2025.105851_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2022.111545","article-title":"Isoform-specific inhibition of FGFR signaling achieved by a de-novo-designed mini-protein","volume":"41","author":"Park","year":"2022","journal-title":"Cell Rep"},{"issue":"6","key":"10.1016\/j.esmoop.2025.105851_bib13","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.1736","article-title":"Monoclonal antibodies that target fibroblast growth factor receptor 2 isoform b and Claudin-18 isoform 2 splicing variants in gastric cancer and other solid tumours","volume":"14","author":"Katoh","year":"2024","journal-title":"Clin Transl Med"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105851_bib14","doi-asserted-by":"crossref","first-page":"4698","DOI":"10.1038\/s41598-021-84107-x","article-title":"Clinical difference between fibroblast growth factor receptor 2 subclass, type IIIb and type IIIc, in gastric cancer","volume":"11","author":"Yashiro","year":"2021","journal-title":"Sci Rep"},{"issue":"5","key":"10.1016\/j.esmoop.2025.105851_bib15","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1111\/cas.16109","article-title":"Whole-transcriptome sequencing in advanced gastric or gastroesophageal cancer: a deep dive into its clinical potential","volume":"115","author":"Hashimoto","year":"2024","journal-title":"Cancer Sci"},{"issue":"10","key":"10.1016\/j.esmoop.2025.105851_bib16","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1158\/1078-0432.CCR-22-0041","article-title":"Transcriptomic profiling of MSI-H\/dMMR gastrointestinal tumors to identify determinants of responsiveness to anti-PD-1 therapy","volume":"28","author":"Chida","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105851_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100762","article-title":"Comprehensive clinical and molecular characterization of claudin 18.2 expression in advanced gastric or gastroesophageal junction cancer","volume":"8","author":"Kubota","year":"2023","journal-title":"ESMO Open"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105851_bib18","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","article-title":"STAR: ultrafast universal RNA-seq aligner","volume":"29","author":"Dobin","year":"2013","journal-title":"Bioinformatics"},{"issue":"7","key":"10.1016\/j.esmoop.2025.105851_bib19","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1093\/bioinformatics\/btt656","article-title":"featureCounts: an efficient general purpose program for assigning sequence reads to genomic features","volume":"30","author":"Liao","year":"2014","journal-title":"Bioinformatics"},{"issue":"12","key":"10.1016\/j.esmoop.2025.105851_bib20","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1093\/bioinformatics\/btw076","article-title":"SplAdder: identification, quantification and testing of alternative splicing events from RNA-Seq data","volume":"32","author":"Kahles","year":"2016","journal-title":"Bioinformatics"},{"issue":"3","key":"10.1016\/j.esmoop.2025.105851_bib21","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s13353-018-0444-7","article-title":"Splicing mutations in human genetic disorders: examples, detection, and confirmation","volume":"59","author":"Anna","year":"2018","journal-title":"J Appl Genet"},{"issue":"12","key":"10.1016\/j.esmoop.2025.105851_bib22","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1038\/nmeth.1528","article-title":"Analysis and design of RNA sequencing experiments for identifying isoform regulation","volume":"7","author":"Katz","year":"2010","journal-title":"Nat Methods"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105851_bib23","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s13059-018-1417-1","article-title":"SUPPA2: fast, accurate, and uncertainty-aware differential splicing analysis across multiple conditions","volume":"19","author":"Trincado","year":"2018","journal-title":"Genome Biol"},{"issue":"12","key":"10.1016\/j.esmoop.2025.105851_bib24","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0051862","article-title":"Cutoff Finder: a comprehensive and straightforward Web application enabling rapid biomarker cutoff optimization","volume":"7","author":"Budczies","year":"2012","journal-title":"PLoS One"},{"issue":"12","key":"10.1016\/j.esmoop.2025.105851_bib25","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1186\/s13059-014-0550-8","article-title":"Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2","volume":"15","author":"Love","year":"2014","journal-title":"Genome Biol"},{"issue":"3","key":"10.1016\/j.esmoop.2025.105851_bib26","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1038\/ng1180","article-title":"PGC-1\u03b1-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes","volume":"34","author":"Mootha","year":"2003","journal-title":"Nat Genet"},{"issue":"43","key":"10.1016\/j.esmoop.2025.105851_bib27","doi-asserted-by":"crossref","first-page":"15545","DOI":"10.1073\/pnas.0506580102","article-title":"Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles","volume":"102","author":"Subramanian","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"11","key":"10.1016\/j.esmoop.2025.105851_bib28","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1007\/s00109-022-02257-5","article-title":"Underlying mechanisms of epithelial splicing regulatory proteins in cancer progression","volume":"100","author":"Liu","year":"2022","journal-title":"J Mol Med (Berl)"},{"issue":"40","key":"10.1016\/j.esmoop.2025.105851_bib29","doi-asserted-by":"crossref","first-page":"27386","DOI":"10.1074\/jbc.M114.589432","article-title":"Epithelial splicing regulatory proteins 1 (ESRP1) and 2 (ESRP2) suppress cancer cell motility via different mechanisms","volume":"289","author":"Ishii","year":"2014","journal-title":"J Biol Chem"},{"issue":"suppl 16","key":"10.1016\/j.esmoop.2025.105851_bib30","article-title":"Trial in progress: Phase 3 study of bemarituzumab + mFOLFOX6 versus placebo + mFOLFOX6 in previously untreated advanced gastric or gastroesophageal junction (GEJ) cancer with FGFR2b overexpression (FORTITUDE-101)","volume":"40","author":"Smyth","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.esmoop.2025.105851_bib31","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1007\/s10120-024-01466-w","article-title":"Bemarituzumab as first-line treatment for locally advanced or metastatic gastric\/gastroesophageal junction adenocarcinoma: final analysis of the randomized phase 2 FIGHT trial","volume":"27","author":"Wainberg","year":"2024","journal-title":"Gastric Cancer"},{"issue":"2","key":"10.1016\/j.esmoop.2025.105851_bib32","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1158\/2159-8290.CD-21-0697","article-title":"Futibatinib, an irreversible FGFR1-4 inhibitor, in patients with advanced solid tumors harboring FGF\/FGFR aberrations: a phase I dose-expansion study","volume":"12","author":"Meric-Bernstam","year":"2022","journal-title":"Cancer Discov"},{"issue":"3","key":"10.1016\/j.esmoop.2025.105851_bib33","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1056\/NEJMoa2206834","article-title":"Futibatinib for FGFR2-rearranged intrahepatic cholangiocarcinoma","volume":"388","author":"Goyal","year":"2023","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.esmoop.2025.105851_bib34","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1111\/cas.70100","article-title":"Landscape analysis of CLDN18 expression and isoform distribution in solid tumors: insights from MONSTAR-SCREEN-2 study","volume":"116","author":"Hashimoto","year":"2025","journal-title":"Cancer Sci"},{"issue":"9","key":"10.1016\/j.esmoop.2025.105851_bib35","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1038\/modpathol.2016.96","article-title":"FGFR2 in gastric cancer: protein overexpression predicts gene amplification and high H-index predicts poor survival","volume":"29","author":"Ahn","year":"2016","journal-title":"Mod Pathol"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105851_bib36","doi-asserted-by":"crossref","first-page":"70","DOI":"10.3390\/cancers12010070","article-title":"Integrated analysis of structural variation and RNA expression of FGFR2 and its splicing modulator ESRP1 highlight the ESRP1amp-FGFR2norm-FGFR2-IIIchigh axis in diffuse gastric cancer","volume":"12","author":"Teles","year":"2019","journal-title":"Cancers (Basel)"},{"issue":"18","key":"10.1016\/j.esmoop.2025.105851_bib37","doi-asserted-by":"crossref","first-page":"5416","DOI":"10.3390\/jcm11185416","article-title":"FGFR-2 and epithelial-mesenchymal transition in endometrial cancer","volume":"11","author":"Adamczyk-Gruszka","year":"2022","journal-title":"J Clin Med"},{"issue":"5","key":"10.1016\/j.esmoop.2025.105851_bib38","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/j.cell.2009.11.007","article-title":"Epithelial-mesenchymal transitions in development and disease","volume":"139","author":"Thiery","year":"2009","journal-title":"Cell"},{"issue":"2","key":"10.1016\/j.esmoop.2025.105851_bib39","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3390\/jcm5020017","article-title":"Role of EMT in metastasis and therapy resistance","volume":"5","author":"Smith","year":"2016","journal-title":"J Clin Med"},{"issue":"10","key":"10.1016\/j.esmoop.2025.105851_bib40","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1038\/ng.2396","article-title":"Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer","volume":"44","author":"Peifer","year":"2012","journal-title":"Nat Genet"},{"issue":"4","key":"10.1016\/j.esmoop.2025.105851_bib41","doi-asserted-by":"crossref","first-page":"3190","DOI":"10.3892\/mmr.2016.4904","article-title":"Knockdown of ephrin receptor A7 suppresses the proliferation and metastasis of A549 human lung cancer cells","volume":"13","author":"Li","year":"2016","journal-title":"Mol Med Rep"},{"key":"10.1016\/j.esmoop.2025.105851_bib42","article-title":"Pan-cancer analysis reveals MTTP as a prognostic and immunotherapeutic biomarker in human tumors","volume":"16","author":"Wang","year":"2025","journal-title":"Front Immunol"},{"issue":"28","key":"10.1016\/j.esmoop.2025.105851_bib43","article-title":"Adipocyte-derived exosomal MTTP suppresses ferroptosis and promotes chemoresistance in colorectal cancer","volume":"9","author":"Zhang","year":"2022","journal-title":"Adv Sci (Weinh)"},{"issue":"11","key":"10.1016\/j.esmoop.2025.105851_bib44","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1111\/pin.12447","article-title":"Cancer stem cells and epithelial-mesenchymal transition: novel therapeutic targets for cancer","volume":"66","author":"Ishiwata","year":"2016","journal-title":"Pathol Int"},{"issue":"5","key":"10.1016\/j.esmoop.2025.105851_bib45","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.molcel.2009.01.025","article-title":"ESRP1 and ESRP2 are epithelial cell-type-specific regulators of FGFR2 splicing","volume":"33","author":"Warzecha","year":"2009","journal-title":"Mol Cell"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105851_bib46","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1186\/s12935-023-03180-6","article-title":"Role of epithelial splicing regulatory protein 1 in cancer progression","volume":"23","author":"Kwon","year":"2023","journal-title":"Cancer Cell Int"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S205970292501720X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S205970292501720X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T23:16:35Z","timestamp":1773270995000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S205970292501720X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":46,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S205970292501720X"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2025.105851","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"FGFR2-IIIc isoform detection reveals prognostic prevalence and a functional link to mesenchymal transition in gastric and gastroesophageal junction cancer","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2025.105851","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"105851"}}